Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Hadi T Nia *Department of Biomedical Engineering, Boston University, Boston, Massachusetts.ORCID 0000-0003-1970-9901
Meenal Datta *Department of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, Indiana.ORCID 0000-0001-5727-8992
Ashwin S Kumar *Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0003-3251-9977
Saeed Siri *Department of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, Indiana.ORCID 0000-0002-4185-0680
Gino B FerraroEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-1587-4259
Sampurna ChatterjeeEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-0850-0328
Jeffrey M McHughDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0008-6897-0253
Patrick R NgDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4566-9173
Timothy R WestDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-6444-6939
Otto RapalinoDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5038-4183
Bryan D ChoiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5090-2470
Brian V NahedDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-8537-106X
Lance L MunnEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-0698-7232
Rakesh K JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7571-3548
Funding
Dissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7M
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
Probing functioning lung at the cellular resolution in health and diseaseDP2HL168562 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI NIA, HADI TAVAKOLI · 2022 to 2025
$2.5M
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3M
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2M
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2R01NS118929 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2021 to 2025
$2.0M
Systems Biology of Antigen and T-Cell Transport in Cancer ImmunotherapyR01CA284603 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Lance L. Munn, TIMOTHY P PADERA · 2023 to 2026
$1.9M
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastomaR01CA269672 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Rakesh K. Jain · 2022 to 2026
$1.9M
Vascularized tumor explants for drug testingR01CA247441 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L. · 2021 to 2025
$1.9M
Establishing an immune mechanomeR35GM151041 · NIGMS · UNIVERSITY OF NOTRE DAME · PI Meenal Datta · 2023 to 2026
$1.7M
Classifying malignant pulmonary nodules using biophysics-enhanced artificial intelligenceR21EB031332 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI NIA, HADI TAVAKOLI · 2021 to 2021
$660k
Agency for Science Technology and ResearchAmerican Brain Tumor Association (ABTA)Beckman Young Investigator AwardJane's TrustLudwig Center at Harvard (Ludwig Center)MGH Fund for Medical DiscoveryNational Foundation for Cancer Research (NFCR)National Institutes of Health (NIH) DP2HL168562National Institutes of Health (NIH) K22-CA258410National Institutes of Health (NIH) R01-CA208205National Institutes of Health (NIH) R01CA247441National Institutes of Health (NIH) R01-CA259253National Institutes of Health (NIH) R01-NS118929National Institutes of Health (NIH) R21EB031332National Institutes of Health (NIH) R35-CA197743National Institutes of Health (NIH) R35-GM151041National Institutes of Health (NIH) U01-CA224348National Institutes of Health (NIH) U01CA261842National Science Foundation (NSF)NCI NIH HHS K22 CA258410NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA247441NCI NIH HHS R01 CA259253NCI NIH HHS R01 CA269672NCI NIH HHS R01 CA284603NCI NIH HHS R35 CA197743NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842NHLBI NIH HHS DP2 HL168562NIBIB NIH HHS R21 EB031332NIGMS NIH HHS R35 GM151041Nile Albright Research Foundation (NARF)NINDS NIH HHS R01 NS118929Pediatric Cancer Research Foundation (PCRF)Sloan Research Fellowship
6 · The paper itself
Abstract
purposePhysical forces exerted by expanding brain tumors-specifically the compressive stresses propagated through solid tissue structures-reduce brain perfusion and neurologic function but heretofore have not been directly measured in patients in vivo. Solid stress levels estimated from tumor growth patterns are negatively correlated with neurologic performance in patients. We hypothesize that measurements of solid stress can be used to inform clinical management of brain tumors. EXPERIMENTAL
designWe developed an intraoperative technique to quantitatively estimate solid stress and brain replacement by the tumor. In 30 patients, we made topographic measurements of brain deformation through the craniotomy site with a neuronavigation system during surgical workflows immediately preceding tumor resection (<5 minutes in the operating room). Utilizing these measurements in conjunction with finite element modeling, we calculated solid stress within the tumor and brain and estimated the amount of brain tissue replaced, i.e., lost, by tumor growth.
resultsMean solid stresses were in the range of 10 to 600 Pa, and the amount of tissue replacement was up to 10% of the brain. Brain loss in patients delineated glioblastoma from brain metastatic tumors, and in mice, solid stress was a sensitive biomarker of chemotherapy response.
conclusionsWe present in this study a quantitative approach to intraoperatively measure solid stress in patients that can be readily adopted into standard clinical workflows. Brain loss due to tumor growth is a novel mechanical-based biomarker that, in addition to solid stress, may inform personalized management in future clinical studies in brain cancer.
Indexed as
Brain NeoplasmsImaging, Three-DimensionalNeuronavigationAdultAgedAnimalsBrainFemaleFinite Element AnalysisGlioblastomaHumansMaleMiddle AgedStress, Mechanical
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Solid Stress Estimations via Intraoperative 3D Navigation in Patients with Brain Tumors. · full record | OpenQuestion